Gene therapy Archives

News and Trends 15 Feb 2017

Optogenetics: What Makes It a Powerful Neuroscience Tool?

It’s a brand-new field and possibilities seem infinite. Here’s what you need to know about its rapid development into a powerful genetic tool. What is Optogenetics? What if you could activate and deactivate neurons by simply switching on the lights? That’s the basis of optogenetics, the control of cell behavior via light-sensitive proteins. Optogenetics is a […]

February 15, 2017 - 3 minutesmins - By External Contributor

lysogene ipo euronext paris e1486638993948

News and Trends 9 Feb 2017

Gene Therapy Biotech Founded to Save the CEO’s Daughter Goes Public in France

Lysogene has raised €22.6M from its IPO on Euronext Paris that will contribute to the completion of clinical trials to treat the rare genetic diseases. Karen Aiach, CEO of Lysogene, started the company back in 2009 to develop a life-saving treatment for her daughter Ornella with Sanfilippo A. This rare genetic disease severely affects the nervous system of […]

February 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Jan 2017

It’s Not Just Regulations: 9 Other Reasons Advanced Therapies Fail

For advanced therapy medicinal products (ATMPs), the regulatory process is a major challenge to reach the market; but it’s only part of the picture. Here are the top 9 other pre-approval reasons these cell and gene therapies fail. Sound Scientific Rationale + Good Product = Successful Outcome.” Paula Salmikangas, Committee for Advanced Therapies (CAT) Chairman […]

January 18, 2017 - 7 minutesmins - By Timothé Cynober

News and Trends 11 Jan 2017

Merck expands its Oncology Pipeline beyond Checkpoint Inhibitors

Merck is diversifying its oncology portfolio with four new programs licensed from Vertex Pharmaceuticals, including multiple DNA damage and repair drugs. Merck has entered a licensing agreement with Boston-based Vertex Pharmaceuticals for the worldwide rights to four oncology programs. Merck has paid €220M ($230M) upfront for two clinical-stage DNA damage and repair candidates and two additional […]

January 11, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 3 Jan 2017

10 Hot European Biotechs to Observe in 2017 🚀

New year, new list: here are the 10 hottest Biotech companies I will watch closely in 2017 and why. This list is not meant to be comprehensive and is in no particular order. Super-pumped mRNA Therapy BioNTech is Europe’s largest private Biotech with over 500 employees and is one of the three leading mRNA therapy […]

January 3, 2017 - 5 minutesmins - By Philip Hemme

News and Trends 26 Dec 2016

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […]

December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Dec 2016

UPDATE: UniQure keeps afloat with a New CEO and More Clinical Data

UniQure’s gene therapy for Hemophilia B is performing well in clinical trials, but the company faces many challenges with its current financial situation. Can it manage to make it to the market? UniQure is famous for launching Glybera, the first globally approved gene therapy, which has been a commercial failure. The company is now indefinitely missing […]

December 20, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 12 16 at 10.22.38 AM e1481880436689

News and Trends 16 Dec 2016

This Gene Therapy Startup is Showing Off with a Better Viral Vector

GeneQuine wants to be one of the first to use gene therapy to treat osteoarthritis! Watch Kilian Guse’s pitch at Labiotech Refresh to find out how his startup plans to do this. “Osteoarthritis is the most common joint disorder. (…) Currently, there are only symptomatic treatments but no disease-modifying treatment“. One of the major challenges is efficient drug […]

December 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 12 Dec 2016

With a new €120M Infusion, Pocket NGS CEO talks Success and Strategy

Seeking to disrupt the NGS market, Oxford Nanopore is rolling in cash. Before we heard the news, we sat down with CEO Gordon Sanghera to talk about the company’s success. December has been a stellar month for Oxford Nanopore. Just over a week ago, Oxford Nanopore’s MinION device was used to sequence the whole genome of a number […]

December 12, 2016 - 9 minutesmins - By Evelyn Warner

News and Trends 29 Nov 2016

New British Partnership set to Cure Rare Diseases with Gene Therapy

Oxford BioMedica and Orchard Therapeutics are partnering up to bring gene therapy to the market and treat rare diseases for which no cure is available yet. Oxford BioMedica develops lentiviral vectors for gene and cell therapy applications. The company just announced a partnership with another biotech from the UK’s golden triangle, Orchard Therapeutics. The deal is […]

November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Nov 2016

UniQure takes an axe to its Pipeline and Workforce in new R&D Strategy

UniQure just announced a new R&D plan designed to save up to €27M over the next two years. Will the new strategy be enough to pull it out of its down spiral? UniQure is a Dutch biotech famous for launching Glybera, the first commercial gene therapy worldwide. However, the huge price of the treatment has […]

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Nov 2016

Meet the CEO making the Next Generation of Gene Therapies Possible

How do you solve a problem like lentiviral vector infections? CEVEC has done it. We sat down with the CEO, Frank Ubags, to talk about his company’s success. The last few decades have not been kind to gene therapy companies, but the field seems to be on the edge of a renaissance with adenoviral vectors […]

November 16, 2016 - 6 minutesmins - By External Contributor

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Gene therapy

Optogenetics: What Makes It a Powerful Neuroscience Tool?

Gene Therapy Biotech Founded to Save the CEO’s Daughter Goes Public in France

It’s Not Just Regulations: 9 Other Reasons Advanced Therapies Fail

Merck expands its Oncology Pipeline beyond Checkpoint Inhibitors

10 Hot European Biotechs to Observe in 2017 🚀

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

UPDATE: UniQure keeps afloat with a New CEO and More Clinical Data

This Gene Therapy Startup is Showing Off with a Better Viral Vector

With a new €120M Infusion, Pocket NGS CEO talks Success and Strategy

New British Partnership set to Cure Rare Diseases with Gene Therapy

UniQure takes an axe to its Pipeline and Workforce in new R&D Strategy

Meet the CEO making the Next Generation of Gene Therapies Possible

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!